Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Januvia
|
| gptkbp:chemicalFormula |
C16H15F6N5O
|
| gptkbp:clinicalTrials |
Phase III
recommended in treatment algorithms |
| gptkbp:commonName |
100 mg once daily
|
| gptkbp:contraindication |
allergic reactions
hypoglycemia pancreatitis hypersensitivity to sitagliptin |
| gptkbp:developer |
gptkb:Merck_&_Co.
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
antidiabetic agent
bioavailability 87% minimal with other drugs |
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:hasAwards |
unknown
|
| gptkbp:hasMuseum |
effective in glycemic control
|
| gptkbp:hasPopulation |
adults with type 2 diabetes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sitagliptin
|
| gptkbp:interactsWith |
warfarin
other antidiabetic medications digoxin |
| gptkbp:lastProduced |
2006
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offers |
moderate
|
| gptkbp:patentExpiration |
2022
|
| gptkbp:researchAreas |
metabolic disorders
weight management diabetes management renal function cardiovascular risk |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
headache
nausea diarrhea nasopharyngitis upper respiratory tract infection |
| gptkbp:targets |
GLP-1 receptor
|
| gptkbp:triggerType |
DPP-4 inhibitor
|
| gptkbp:usedFor |
type 2 diabetes
|
| gptkbp:variant |
metformin
simvastatin glimepiride |
| gptkbp:waterManagement |
urine
|